TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2017 financial and operating results after the close of U.S. financial markets on Wednesday, February 28, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:
Date:	February 28, 2018
Time:	4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in:	(855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode:	1894785
Via web:	www.traconpharma.com; “Events and Presentation” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Company Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
Andrew@lifesciadvisors.com